Inaktiver Wert

Andere Sprachen Biostage Inc Nasdaq

Aktien

US41690A1060

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

28.03.	Harvard Apparatus Regenerative Technology Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Harvard Apparatus Regenerative Technology Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Harvard Apparatus Regenerative Technology : Q1 - 2024 HBIO Quarterly Earnings Presentation	07.05.
Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	15.04.
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Harvard Apparatus Regenerative Technology : March 19, 2024 - Investor Presentation	18.03.
Harvard Apparatus Regenerative Technology : Q4 - 2023 HBIO Quarterly Earnings Presentation	07.03.
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Harvard Apparatus Regenerative Technology : Northland Capital Markets Institutional Investor Conference 2023	18.09.23
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14.08.23
Harvard Apparatus Regenerative Technology : Q2 - 2023 HBIO Quarterly Earnings Presentation	08.08.23
Biostage Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	19.07.23
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	18.07.23
Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	15.06.23
Biostage to Host Investor Call	13.06.23
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease	31.05.23
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31.05.23
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31.05.23
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12.05.23
Biostage, Inc. announced that it has received $6.005802 million in funding	13.04.23
BIOSTAGE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	10.04.23
Biostage Appoints Ron Packard to Board of Directors	10.04.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Biostage Inc Nasdaq

Aktien

US41690A1060

Andere Sprachen

Filter